Background: Immunosuppressive therapy (methotrexate and biological agents) for juvenile idiopathic arthritis (JIA) is associated with an increased risk of severe infections, higher infection rates, treatment interruptions, failure to achieve disease remission, recurrent flares. Our study aimed evaluate the safety efficacy simultaneous immunization 13-valent polysaccharide conjugate vaccines (PCV13) against S. pneumoniae (SP) Hemophilus influanzae type b infections (HibV) in children JIA...

Background A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack efficacy or safety concerns. Studies therapy switch regimens in sJIA are required. Methods Patients with who switched from tocilizumab (due safety) canakinumab (4 mg/kg every 4 weeks) and were hospitalized at the rheumatology department August 2012 July 2020 included. Primary outcomes 30% greater improvement based on...

The aim of this study was to investigate the efficacy etanercept treatment and identify predictors response therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.A total 197 were enrolled study. Response assessed using ACRPedi 30/50/70/90 criteria, Wallace Juvenile Arthritis Disease Activity Score 71 (JADAS-71). Univariate multivariate logistic regression analyses performed potential baseline factors associated different JIA...

Aim: To create the Russian-language version of standardized international questionnaire Health Utilities Index (HUI) applicable for children's age, on basis relevant requirements to linguistic ratification and validation tools. Patients methods : 427 children first 233 second health group have taken part in research. Average age patients made 10.8 ± 4.6 years. Criteria validity HUI was assessed by comparison patients' answers who had different status, a convergent — attributes with scales...

Introduction The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D cryopyrin-associated but this treatment has not been assessed patients with undifferentiated AIDs (uAIDs). Our study aimed to assess the safety efficacy canakinumab uAIDs. Methods Information on 32 uAIDs was...

Both the steroid- and NSAID-sparing effects of biologics in juvenile idiopathic arthritis (JIA) treatment are key aspects dynamics patient's condition. The proper selection enables maximum effectiveness reduction dosage concomitant therapy. Our aim was to study therapy during etanercept (ETA) methotrexate (MTX) patients with JIA.This analysis included 215 JIA (63.3% females) showing sufficient response main One hundred received MTX as therapy, 24 ETA monotherapy, 91 þ combination were...

Introduction. Currently, there are still problems in the rehabilitation of children with chronic diseases and disabilities, as well establishment disability itself, which is primarily due to lack common criteria for describing health, functioning child’s body, their disorders at different ages assessing effectiveness measures. Purpose. To develop disturbance suffered from various disabling terms quality life. Materials methods. By means developed Russian-language version standardized...

The results of the retrospective study evaluating efficacy and safety tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented paper. Inactive disease was documented 64% after 6 months 73% 12 months. Adverse events manifested as mild moderate infections well laboratory abnormalities: leukopenia, neutropenia, elevated aminotransferase levels.

Objective: The aim of this study was to analyze the efficacy and safety etanercept (ETA) in children with juvenile idiopathic arthritis (JIA) under age 4 years compare data those for older groups. Methods: Three groups comprising 34 patients each (total 102 patients) were selected using propensity score matching (PSM) method. group (patients years; Junior (JNR)) compared groups, adjusted criteria such as gender, JIA category, severity, either at disease onset (the Reference by Age Onset...

Aim : to assess efficacy and safety of «changeover» the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) resistance or intolerability first GEBA. Patients methods results retrospective observational research GEBA 136 various variants JIA aged from 1 17 years old primary resistance, partial effect loss other agents are shown this article. Among those 41 patient have systemic 95 — without extra-articular involvement. In 32 involvement...

Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease of childhood. The goal juvenile therapy to achieve durable clinical and laboratory remission a good quality life. Various groups drugs are used in treatment JIA, one which anti-CD20 drug rituximab. Rituximab causes B-cell depletion, may lead decreased immunoglobulin levels, antigen-presenting function B-lymphocytes impaired T-cell response. main side effects rituximab administration infusion reactions,...

The efficacy of JAK-kinase inhibitors in autoimmune diseases is due to the peculiarities their pathogenesis, involvement various cytokines that trigger cascade inflammatory reactions, enhance transcriptional response disease-induced or disease-associated genes and potentiate production proinflammatory cytokines. Only tofacitinib currently approved for use pediatric rheumatic diseases. Given literature data on other adult diseases, we assume possibility patients. Objective. To evaluate safety...

Systemic juvenile idiopathic arthritis (sJIA) is of one or more joints accompanied preceded by confirmed intermittent fever at least 3 days duration for 2 weeks in combination with the following features: transient (volatile) erythematous rash, generalized lymphadenopathy, hepatomegaly and/or splenomegaly, serositis. Prior to invention genetically engineered biological drugs (GEBDs), therapeutic options patients JIA were limited use nonsteroidal anti-inflammatory (NSAIDs),...

New coronavirus infection (COVID-19) is an acute respiratory disease caused by the SARS-CoV-2 coronavirus. Tixagevimab+cilgavimab has been developed for prevention and treatment of COVID-19. The purpose this research was to evaluate safety use two-component drug monoclonal antibodies (tixagevimab+cilgavimab) pre-exposure prophylaxis new in children with rheumatic diseases (RDs). Materials methods used: a single-center retrospective study prospective stage had carried out that included 300...

Severe acute respiratory syndrome virus SARS-CoV-2 is associated with the phenomenon of immune system dysregulation, which may serve as a trigger for development autoimmune diseases and secondary hemophagocytic (vHPS). Objective. To determine peculiarities clinical laboratory manifestations sHPS in children rheumatic (RD) developed after NCI (COVID-19). Patients methods. The study included 116 pediatric patients RH who underwent examination treatment at rheumatology department National...

Aim : to assess efficacy and safety of hypodermic methotrexate injections in children aged from 1,5 16 years old with juvenile idiopathic arthritis (JIA) without extra-articular manifestations. Patients methods the results treatment 104 patients JIA systemic manifestations (61 girls 43 boys) 5,0 (1,5–16) being followed-up rheumatology department FSFI «SCCH» RAMS were analyzed. The mean duration disease at moment first administration was 6 months. Efficacy therapy assessed according pediatric...

Aim: to carry out a retrospective analysis of efficacy and safety tocilizumab treatment in children with severe resistant forms systemic juvenile idiopathic arthritis. Patients methods : 75 patients (35 girls 40 boys) aged 8,8 (6; 12) years old arthritis routine immunosuppressive therapy were included the study. The mean duration disease before administration was 3,2 (1,9; 5,2) years. diagnose made based on ILAR criteria. All performed standard clinical laboratory examination. assessed...

Rationale. Children with rheumatic diseases receiving immunosuppressants and/or genetically engineered biopharmaceutical drugs (GEBDs) glucocorticosteroids (GCs) are at high risk of developing severe long-term symptoms novel coronavirus infection. The possibilities pre-exposure prophylaxis COVID-19 in this patient population significantly limited due to the risks insufficient immunogenicity vaccine presence secondary immunodeficiency developed under conditions immunosuppressive therapy and...

The aim of the study was to assess efficacy and safety etanercept treatment in combination with methotrexate 32 patients juvenile idiopathic arthritis primary secondary inefficiency intolerance infliximab. In 1 month after switching improvement achieved 84% patients, 50% — 66%, 70% 55% according ACR pedi criteria. 6 months non-active stage registered all patients. Remission established 85% children 9 months, 12 months. Etanercept well-tolerated majority side-effects were mild or moderate,...

Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied. Objective. Our aim was reveal early therapy JIA symptoms. Methods. A retrospective cohort study enrolled who received between July 2009 and August 2017. We assessed association initial demographic, clinical, laboratory parameters best (according...

Introduction: In 2011, Etanercept (ETA) was approved for clinical application in patients with Juvenile Idiopathic Arthritis (JIA) older than 2 years of age; Adalimumab (ADA) 2013. However, the available data these are not sufficient even large-scale registers. children, uveitis is a factor taken into consideration when choosing anti-TNF therapy, so we believe that its onset at an early age may affect efficacy treatment different drugs. Objectives: This study aimed to evaluate comparative...

New biologics developed to treat juvenile idiopathic arthritis (JIA) and the broadening range of indications for young children offer new drug switch options if first-line treatment has proved ineffective. Nevertheless, question regarding selection optimal medication depending on patients' characteristics prior therapy still needs be solved. To evaluate efficacy safety adalimumab (ADA) as first subsequent biologic in under 4 years age. Analysis was performed using Research Center Children’s...

Background . Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates the genetically engineered biologic drugs (GEBD) effects on vaccination results also remain controversial. Objective The aim study was to explore PCV-13 efficacy patients SJIA and who treatment monoclonal antibodies against interleukin 6 receptor (tocilizumab) 8 beta (canakinumab). Methods included under age 18 remission or...

Inflammation and glucocorticoid therapy are major factors in the growth retardation seen children with severe forms of juvenile idiopathic arthritis (JIA).

Aim : To assess the influence of genetically engineered biologic drug etanercept on quality life patients with juvenile idiopathic arthritis (JIA). Patients and methods The research included 85 children poly-and oligoarticular variant JIA at age 5 (2; 17) years. assessment was carried out by means parental version a special questionnaire CHAQ (Childhood Health Assessment Questionnaire), Utilities Index Mark 3 (HUI3) questionnaire. doctor parents patient also assessed global activity illness...